| HTA ID | Drug | Brand | Indication | Assessment status | Date | |
| 20008 | Ruxolitinib | Jakavi® | For the treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea. | Assessment Process Complete | 21st July 2021 |  |
| 25004 | Ruxolitinib | Opzelura® | Ruxolitinib (Opzelura®) is indicated for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. | Rapid Review Complete | 17th February 2025 | |
| Cookie | Duration | Description |
|---|---|---|
| cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
| cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
| cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
| cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
| cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
| viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
